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Aneurysmal dilatation of this segment occurs less fre-
quently with time, in contrast to that of the more distal
infrarenal aorta.3
Fixation of the endovascular graft in the more stable
transrenal segment of the aorta has been demonstrated to
reduce the incidence of proximal endoleak in patients with
complex infrarenal aortic morphology.4 The safety and
efficacy of the transrenally placed uncovered stent has
been reported.4-10 The close proximity of the superior
mesenteric and celiac arteries to the renal arteries may lead
to frequent extension of the uncovered stent to the level
of the superior mesenteric artery (SMA) or celiac axis dur-
ing placement of a transrenally fixated endograft. In this
study, the impact of transmesenteric deployment of the
uncovered proximal aortic stent on visceral perfusion was
analyzed to find which of the visceral arteries were crossed
by the proximal uncovered stent struts and the subsequent
development of significant mesenteric vascular sequelae.
PATIENTS AND METHODS
Database and patient demographics. From January
1997 to June 1999, all patients undergoing endovascular
repair of an AAA at Mt. Sinai Medical Center were entered
prospectively into a vascular registry. These data were then
reviewed retrospectively to find the impact of transvisceral
aortic fixation. All patients were considered for endografting
in accordance with an investigator-sponsored Investigational
Endovascular grafting is currently being evaluated as
an alternative method for repair of appropriately selected
abdominal aortic aneurysms (AAAs). The potential advan-
tages of endovascular AAA repair have been discussed at
length and include decreased morbidity, mortality, and
length of stay and a lower overall treatment cost.1
However, not all AAAs are amenable to endovascular
repair. Anatomic features of the infrarenal aortic neck such
as severe angulation, thrombus, or a short (< 2cm) renal
artery-to-aneurysm distance may preclude endovascular
repair with current commercially available U.S. Food and
Drug Administration-approved devices.2 The pararenal
segment of the aorta is frequently preserved in these
patients, even in the presence of a difficult infrarenal neck.
109
From the Division of Vascular Surgery, Department of Surgery, Mount
Sinai School of Medicine.
Competition of interest: nil.
Presented at the Twenty-ninth Annual Meeting of the Society for Clinical
Vascular Surgery, Boca Raton, Fla, Apr 4-7, 2001.
Reprint requests: Michael L. Marin, MD, Henry Kaufman Professor of
Surgery, Division of Vascular Surgery, Department of Surgery, Mount
Sinai Medical Center, 5 East 98th St, Box 1273, New York, NY (e-mail:
michael.marin@mssm.edu).
Published online Nov 1, 2001.
Copyright © 2002 by The Society for Vascular Surgery and The American
Association for Vascular Surgery.
0741-5214/2002/$35.00 + 0 24/6/119387
doi:10.1067/mva.2002.119387
Endovascular repair of abdominal aortic
aneurysms: Stent-graft fixation across the visceral
arteries
James A. Burks, Jr, MD, Peter L. Faries, MD, Edwin C. Gravereaux, MD, Larry H. Hollier, MD, and
Michael L. Marin, MD, New York, NY
Purpose: Recent studies have suggested that transrenal artery fixation of endovascular stent-grafts is safe and may be a
desirable means of reducing the risk of type I endoleaks, particularly those with short infrarenal necks. The close prox-
imity of the superior mesenteric and celiac arteries to the renal arteries may commonly result in the placement of the
stent struts across all the vessels of the visceral segment of the aorta. The purpose of this study was to determine the
incidence and impact of transvisceral artery fixation during aortic stent-graft deployment for the treatment of abdom-
inal aortic aneurysms (AAAs).
Methods: From January 1997 to June 1999, 192 patients (165 men, 27 women; mean age, 82 years) with AAAs were
treated with an endovascular graft secured proximally to the aorta with a long (15 mm) uncovered stent segment (60
Parodi/Palmaz, 132 Talent-LPS). Preoperative and postoperative abdominal aortograms and intravenous contrast
enhanced spiral computed tomography (CT) scans were performed. Follow-up CT scans were obtained at 3, 6, and 12
months and yearly thereafter as a means of determining stent position and visceral artery patency.
Results: In 95 patients (49%), the uncovered stent was at or above the level of the superior mesenteric artery. In 23
patients (12%), the stent extended to the level of the celiac axis. In a mean follow-up period of 25 months (range, 6-
44 months), serum creatinine levels remained stable, no stenoses or occlusions occurred in the celiac, superior mesen-
teric, or renal arteries, and no evidence of renal, hepatic, splenic, or intestinal infarction was present on contrast
enhanced spiral CT scans. There were no type I endoleaks.
Conclusion: Transvisceral fixation of the uncovered proximal aortic stent occurs frequently during deployment of
devices designed for transrenal fixation and is associated with no early morbidity. Long-term follow-up is necessary to
ensure that there are no late sequelae. (J Vasc Surg 2002;35:109-13)
Device Exemption from the U.S. Food and Drug Admin-
istration, with approval of the Mount Sinai Medical Center
Institutional Review Board. Informed consent was obtained
from all patients. During this period, 192 patients under-
went endovascular repair of an AAA with a stent graft device
incorporating a long (15 mm) uncovered proximal stent (60
Parodi/Palmaz, 132 Talent-LPS). All patients were at high
risk for conventional open repair because of significant car-
diac or pulmonary comorbidities (Table I). Each patient
underwent spiral computed tomography (CT) and abdomi-
nal aortography preoperatively for procedure planning pur-
poses. The serum creatinine level of each patient was
measured preoperatively. The indication for surgery in all
patients was an AAA with a diameter ranging from 5.0 to
10.3 cm (mean, 6.1 cm).
Devices. Patients were treated with either a home-
made Parodi/Palmaz (Fig 1) or commercially produced
Talent-LPS (Fig 2) stent-graft device. The Parodi/Palmaz
stent-grafts were fashioned individually by the surgeon.
The device consisted of a Palmaz stent (30 mm, Johnson
and Johnson, Sommerville, NJ) sutured to an expanded
polytetrafluoroethylene conduit (Impra, C.R. Bard,
Murray Hill, NJ). The proximal-most 15 mm of the stent
was left uncovered and secured with balloon expansion in
the transrenal position during deployment. The Talent-
LPS aortic stent-graft was a modular system composed of
a nitinol wire frame supporting a thin-walled polyester
graft. Proximal aortic fixation was achieved in the transre-
nal aortic segment by using a 15-mm length of uncovered
self-expanding nitinol stent (Fig 4). Deployment of the
proximal fixation device was carried out with C-arm fluo-
roscopy at oblique and cranio-caudad angles 90° to the
axis of the aortic neck. A parallel pigtail multiholed
catheter was used for contrast injection as a means of guid-
ing proximal deployment. Transrenal fixation of the device
was used routinely as a means of minimizing the length of
uncovered aorta between the renal arteries and the begin-
ning of the cloth portion of the stent-graft. Characteristics
of the proximal aortic neck that accentuated the advan-
tages of this configuration included significant neck angu-
lation or short (< 1.5 cm) neck length.
Follow-up studies. In each patient, intraoperative
completion angiography of the visceral aortic segment,
endograft, and outflow femoral vessels was performed in
two views. All patients underwent a follow-up physical
examination, serum creatinine level measurement, and
contrast-enhanced spiral CT examination extending from
the diaphragm to the femoral arteries at 3, 6, and 12
months and annually thereafter. Intraoperative completion
arteriograms and postoperative contrast-enhanced spiral
CT scans were examined to determine the proximal extent
of the uncovered stent strut.
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Fig. 1. The Parodi/Palmaz surgeon-made aortouniiliac aortic
endograft device has a 30-mm balloon-expandable Palmaz stent
sutured to the proximal end of a tapered (28 mm to 8 mm)
expanded polytetrafluoroethylene graft.
Fig. 2. The Talent-LPS aortic endograft device is a modular
system with a nitinol wire frame supporting a thin-walled poly-
ester graft.
RESULTS
Of 192 endografts placed, 97 (51%) were fixed to the
infrarenal or transrenal segment, whereas 95 (49%) had
transvisceral fixation (Table II). Of the 95 transviscerally
placed endografts, 72 (37%) were placed so that the prox-
imal uncovered stent struts extended across the origin of
the SMA and the renal arteries (Fig 3), and 23 (12%)
showed extension of the stent struts to the level of the
celiac artery origin (Fig 4). In no case were any of the vis-
ceral artery orifices even partially occluded by the graft
itself, although two patients early in the series had inad-
vertent coverage of one renal artery by the cloth portion
of the graft.
In a mean period of 25 months (range, 6-44 months),
the 95 patients with transvisceral fixation were examined,
and follow-up spiral CT angiograms were analyzed for evi-
dence of stenosis, occlusion, or thromboembolism within
the visceral arteries. No visceral artery stenoses, occlu-
sions, or radiologically or clinically evident bowel ischemia
occurred. There was also no evidence of renal, hepatic, or
splenic infarction.
The median serum creatinine level, excluding that of
the two patients with inadvertent renal artery coverage,
was not significantly changed after endografting (preoper-
ative median, 0.9 mg/dL; preoperative range, 0.5-2.7
mg/dL; postoperative median, 0.8 mg/dL; postoperative
range, 0.5-2.4 mg/dL). Both patients with malpositioned
stent grafts and unilateral renal artery coverage had unilat-
eral renal infarction and a significant, irreversible rise in
postprocedural creatinine level, from 1.1 to 2.4 mg/dL
and from 0.9 to 2.9 mg/dL, respectively. Neither patient,
however, went on to require dialysis.
Overall, 37 of 95 patients (39%) had postoperative
complications (Table III). There were two perioperative
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deaths (2.1%), both caused by cardiopulmonary complica-
tions. There have been no postprocedural aneurysm rup-
tures. Six patients have had subsequent graft limb
occlusions. One patient had respiratory failure requiring
prolonged intubation. Three patients had postoperative
acute tubular necrosis, in two cases caused by inadvertent
unilateral renal artery graft coverage and in one case with-
out any evidence of renovascular impairment found by
means renal scan or duplex ultrasound scanning. Four
wound complications occurred. There were 19 endoleaks
(0 type I, 19 type II).
DISCUSSION
Multiple factors make endovascular aneurysm repair
attractive to surgeons and patients alike. The less-invasive
nature of the procedure allows the patient with severe
comorbidities that would preclude conventional surgical
repair to undergo exclusion of the aneurysm and prevents
potential aneurysm rupture. Unfortunately, the currently
available commercial devices for endovascular aneurysm
repair are contraindicated when certain common anatomic
features of the diseased aorta exist. These include a short
(< 2 cm), thrombus-lined, or severely angulated proximal
neck. There is also considerable evidence that the
infrarenal aorta may dilate with time, leading to potential
device migration.3
In an effort to extend the indications for endovascular
repair to include this relatively large subset of patients, sev-
eral investigators have proposed and reported on the
safety and efficacy of transrenal stent-graft fixation. It has
been suggested that by anchoring the endovascular graft
in the undilated pararenal aorta, early and late endoleak
and device migration may be prevented, even in cases in
which there is an angulated, short, or thrombus-lined
proximal aortic neck. A significantly decreased risk of
proximal type I endoleak without any increase in early
morbidity or risk of renal dysfunction has been reported in
patients treated with transrenal stent-graft fixation as
Table I. Patient demographics
Characteristic Number of patients (%)
Male 84 (88)
Smoker 60 (63
Coronary artery disease 59 (62)
Chronic obstructive pulmonary disease 21 (22)
Hypertension 56 (59)
Congestive heart failure 5 (5)
End-stage renal disease 5 (5)
Malignancy 14 (15)
Earlier abdominal surgery 8 (8)
Table II. Device type and level of proximal fixation
Trans-SMA Trans-celiac
Device type fixation fixation
Parodi/Palmaz 16 (17%) 8 (8%)
Talent-LPS 56 (59%) 15 (16%)
Total 72 (76%) 23 (24%)
SMA, Superior mesenteric artery.
Fig. 3. CT scan without intravenous contrast demonstrating
stent struts projecting across the origin of the SMA.
opposed to infrarenal fixation.4 However, transrenal fixa-
tion alone does not ensure prevention of type I endoleaks.
When we reviewed our experience with transrenal
stent graft fixation, it became clear that, because of the
longitudinal proximity of the SMA and celiac artery ori-
gins to the renal arteries, in many cases the uncovered
stent struts were crossing portions of the mesenteric vis-
ceral vessels. The SMA and celiac and renal arteries are
generally spaced within a 2-cm segment of the abdominal
aorta.15 Given the close proximity of these vessels, the
stent-graft geometry (1.5 cm proximal uncovered stent),
and the technique of preferably placing the proximal por-
tion of the graft immediately below the lowest renal artery,
it is not surprising that nearly 50% of the patients who
intended to have transrenal stent-graft fixation actually
had pan transvisceral fixation. Despite the potential con-
cerns of “caging” the visceral vessels, including acute
mesenteric ischemia caused by thrombosis, mesenteric
embolization, and progressive occlusion of the visceral
vessels leading to chronic mesenteric ischemia, we have
seen no clinically evident mesenteric vascular complica-
tions in a mean follow-up period of more than 2 years. No
evidence of occlusions, thromboses, or emboli to the vis-
ceral vessels, liver, or spleen was revealed by means of a
review of all follow-up contrast-enhanced spiral CT scans.
As a result, we concluded that transvisceral stent deploy-
ment may be safely performed during endovascular repair
of AAAs.
Earlier studies have shown that transrenal artery stent
graft fixation of aortic endografts is safe and likely prevents
type I proximal endoleaks, particularly in patients with
short, angulated, or thrombus-lined proximal aortic
necks.4,16 We have found in this study that pan transvis-
ceral artery stent-graft fixation is common during place-
ment of aortic endografts designed for transrenal artery
fixation. Fortunately, we have found this “caging” of the
visceral vessels to be associated with no increase in early
complications, and in a mean follow-up period of more
than 2 years, we have seen no mesenteric vascular compli-
cations in this large group of patients.
Another potential downside to placement of a large
stent in the visceral segment of the aorta is clamp place-
ment should conversion to open repair become necessary.
The presence of a stent in the visceral segment of the aorta
will mandate supraceliac clamping and thus increase the
difficulty and morbidity rate of the procedure, especially
when it is performed in an acute setting.
Transrenal artery stent graft fixation is well established
as a safe and effective means of preventing proximal type I
endoleaks and may extend the indications for aortic endo-
grafting to a large subset of patients who might otherwise
be excluded because of difficult aortic anatomy. This study
found that a significant proportion of these patients have
actually had their stent-graft devices anchored within the
visceral aortic segment superior to the renal arteries with-
out any apparent increase in morbidity. Although these
intermediate-term results suggest that pan transvisceral
artery fixation is also safe and effective, long-term follow-
up is necessary to ensure that there are no unforeseen late
sequelae.
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